- Home
- GMAB vs BNT Comparison
GMAB vs BNT Comparison
Compare GMAB & BNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BNT
- Stock Information
- Founded
- GMAB 1999
- BNT 2020
- Country
- GMAB Denmark
- BNT Bermuda
- Employees
- GMAB N/A
- BNT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BNT
- Sector
- GMAB Health Care
- BNT
- Exchange
- GMAB Nasdaq
- BNT Nasdaq
- Market Cap
- GMAB 17.4B
- BNT 18.9B
- IPO Year
- GMAB N/A
- BNT N/A
- Fundamental
- Price
- GMAB $32.12
- BNT $68.06
- Analyst Decision
- GMAB Strong Buy
- BNT
- Analyst Count
- GMAB 7
- BNT 0
- Target Price
- GMAB $41.17
- BNT N/A
- AVG Volume (30 Days)
- GMAB 2.2M
- BNT 21.1K
- Earning Date
- GMAB 11-05-2025
- BNT 11-13-2025
- Dividend Yield
- GMAB N/A
- BNT 0.53%
- EPS Growth
- GMAB 77.72
- BNT N/A
- EPS
- GMAB 21.62
- BNT 2.78
- Revenue
- GMAB $3,646,881,232.00
- BNT $14,371,000,000.00
- Revenue This Year
- GMAB $24.25
- BNT N/A
- Revenue Next Year
- GMAB $16.29
- BNT N/A
- P/E Ratio
- GMAB $1.51
- BNT $24.33
- Revenue Growth
- GMAB 32.97
- BNT 57.06
- 52 Week Low
- GMAB $17.24
- BNT $43.69
- 52 Week High
- GMAB $33.63
- BNT $74.16
- Technical
- Relative Strength Index (RSI)
- GMAB 72.36
- BNT N/A
- Support Level
- GMAB $28.36
- BNT N/A
- Resistance Level
- GMAB $33.63
- BNT N/A
- Average True Range (ATR)
- GMAB 0.62
- BNT 0.00
- MACD
- GMAB 0.11
- BNT 0.00
- Stochastic Oscillator
- GMAB 72.68
- BNT 0.00
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. It is organized into three reporting segments: Direct Insurance, Reinsurance, and Pension Risk Transfer (PRT).